Pharmaceutical - Daiichi Sankyo, Markets & Marketing

Filter

Popular Filters

Daiichi Sankyo launches blood thinner Efient in Japan

27-05-2014

Daiichi Sankyo said this morning that it has launched its anti-blood clotting drug Efient (prasugrel…

Cardio-vascularDaiichi SankyoEfientJapanMarkets & MarketingPharmaceuticalRegulation

Daiichi Sankyo launches Biopten Granules 10% in Japan

Daiichi Sankyo launches Biopten Granules 10% in Japan

29-11-2013

Japanese drug major Daiichi Sankyo has launched natural tetrahydrobiopterin agent Biopten Granules 10%…

Asia-PacificBioptenDaiichi SankyoMarkets & MarketingPharmaceuticalRare diseases

Japan briefs: Daiichi Sankyo launches silodosin in China; Fujifilm Diosynth UK unit commissioned

22-04-2013

Japanese drug major Daiichi Sankyo says that its subsidiary, Daiichi Sankyo Pharmaceutical (Beijing),…

Asia-PacificBiotechnologyDaiichi SankyoEuropeFujifilm Diosynth BiotechnologiesMarkets & MarketingPharmaceuticalProductionsilodosinUrief

Daiichi Sankyo and Ranbaxy to launch branded generics in Brazil

21-04-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority (64%)-owned Indian affiliate Ranbaxy…

Daiichi SankyoGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSouth America

Kowa and Daiichi Sankyo to end joint marketing partnership in Japan

07-04-2013

Privately-held Japanese drugmaker Kowa and pharma major Daiichi Sankyo (TYO: 4568) say they will be ending…

Asia-PacificCardio-vascularDaiichi SankyoKowa PharmaceuticalsLicensingLivaloMarkets & MarketingOlmetecPharmaceutical

Brazil's atrial fibrillation market expected to grow at 31% pa over next five years

22-01-2013

The Brazilian market for atrial fibrillation will increase at a rate of 31% per year from 2011 to 2016,…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularDaiichi SankyoEliquisLixianaMarkets & MarketingPharmaceuticalPradaxaSouth AmericaXarelto

Daiichi Sankyo and Ranbaxy combine business operations in Thailand

16-01-2013

Japanese pharma major Daiichi Sankyo (TYO: 4568) and its 64%-owned affiliate Ranbaxy Laboratories (AB:…

Asia-PacificDaiichi SankyoGenericsManagementMarkets & MarketingPharmaceuticalRanbaxy Laboratories

Brazil's atrial fibrillation market to grow at 31% annually over the next five years

19-12-2012

The Brazilian market for atrial fibrillation will increase at a rate of 31% per year from 2011 to 2016,…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularDaiichi SankyoEliquisLixianaMarkets & MarketingPfizerPharmaceuticalPradaxaPricingSouth AmericaXarelto

Sales of cancer pain therapies set to grow to $5.2 billion in the G7 by 2021

13-12-2012

Sales of cancer pain therapies will increase to $5.2 billion in 2021 in leading seven markets (the USA,…

AmgenBiotechnologyDaiichi SankyodenosumabGlaxoSmithKlineGlobalMarkets & MarketingOncologyPharmaceuticalRanmarkXgeva

Ranbaxy Labs' Absorica debuts in USA

27-11-2012

Indian drugmaker Ranbaxy Laboratories (AB: BO), which is majority owned by Japan's Daiichi Sankyo, said…

AbsoricaCipher PharmaceuticalsDaiichi SankyoDermatologicalsGalephar Pharmaceutival ResearchGenericsMarkets & MarketingNorth AmericaPharmaceuticalRanbaxy Laboratories

Daiichi Sankyo and Ranbaxy debut hybrid business model in Venezuela

20-06-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) announced that its Daiichi Sankyo Venezuela unit would…

Daiichi SankyoGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSouth America

Ranbaxy debuts first Indian-developed malaria drug, Synriam

27-04-2012

Indian drug major Ranbaxy (AB: B) said yesterday - coinciding with World Malaria Day - that it is "opening…

Asia-PacificDaiichi SankyoMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSynriamTropical diseases

Daiichi Sankyo and Ranbaxy launch Sevikar in Romania

19-04-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority-owned Indian subsidiary Ranbaxy Laboratories…

Cardio-vascularDaiichi SankyoEuropeGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSevikar

Daiichi Sankyo debuts bone cancer drug Ranmark in Japan

17-04-2012

Following National Health Insurance price listing yesterday, Japanese drug major Daiichi Sankyo (TYO:…

AmgenAsia-PacificAstraZenecaBiotechnologyDaiichi SankyodenosumabMarkets & MarketingOncologyPharmaceuticalRanmark

Daiichi Sankyo admits supply problem with flu vaccine; gains approval for silodosin in China

23-09-2011

Japanese drug major Daiichi Sankyo (TYO: 4568) announced this week that its domestic subsidiary, Kitasato…

Asia-PacificDaiichi SankyoMarkets & MarketingOncologyPharmaceuticalRegulationsilodosinVaccines

Back to top